



4th Annual Biomedical Forum

March 28, 2009

Welcome to the 4th Annual Biomedical Forum. This year’s program will focus on the latest innovations in medical devices and biotechnology/ pharmaceutical industries, as well as business opportunities to thrive in the new economy amid global financial challenges. The mission of this forum is to provide an attractive platform for entrepreneurs, scientists, engineers, investors, executives, and policy makers to promote life sciences, biotechnology, pharmaceutical, medical device and alliances across the biomedical industry in Southern California and Asia. The annual biomedical forum is one of the flagship events organized by SABPA OC/LA, which consistently attracted more than 200 attendees. This year, we have brought to you pioneers and greatest innovators in the field, as well as exhilarating entrepreneurs that help accelerate the development of technology into clinical practices. Furthermore, we will introduce two Special Reports from China to join the discussion on reviving the economy from global operation perspective. I hope you will enjoy the program.

Hengchu Cao, Ph.D.
President, SABPA OC/LA

Program

8:00 am	Registration Coffee and Breakfast
8:15 am	Opening Remarks Hengchu Cao , PhD, President, SABPA OC/LA William Tang , PhD, Associate Dean of Research, Henry Samueli School of Engineering, UC Irvine
Section I	Innovation in Medical Device Industry Moderator: Shouyan Lee , PhD, Medical Implant Mechanics, LLC
8:30 am	Rob Michiels , Chief Operating Officer, CoreValve Inc. <i>“Transformation in Heart Valve Replacement”</i>
9:10 am	Peter Chen , PhD, President, Center for Innovation and Strategic Collaboration, St. Jude Medical , Inc. <i>“Innovations in Cardiac Rhythm Management and Neuromodulation Devices”</i>
9:50 am	Stan Rowe , Chief Scientific Officer, Corporate Vice President, Edwards Lifesciences LLC <i>“Practical Innovations in Cardiac Disease Management”</i>
10:30 am	Coffee Break

Section II	Trends in Global Biotech and Pharmaceutical Industry Moderator: Alex Qiu , MD, PhD, Allergan, LLC
10:50 am	Mitchell Brin , MD, Senior Vice President, Global Drug Development & Chief Scientific Officer, Allergan , LLC. & Clinical Professor of Neurology, University of California , Irvine <i>“The Development of BOTOX®”</i>
11:30 am	David Ke , MD, Executive Scientific Director, Amgen , Inc. <i>“Transforming Basic Science To Drug Discovery: The Story Of Sclerosteosis And Development Of Anti-Sclerostin Monoclonal Antibody”</i>
12:10 pm	Lunch and visit Exhibit Booth

Section III	Global Business Operations Panel: IP, Tax, and Regulatory Strategies Moderator: Scott Lopez , Biotronik, Inc.
1:10 pm	Sabing Lee , JD, Knobbe, Martens, Olson & Bear, LLP <i>"Commercialization of Life Sciences/Medical Devices: Intellectual Property-What You Need to Know"</i>
	Cliff Guan , Senior Manager, International Tax – China Desk Leader, Deloitte Tax LLP <i>"Business Landscape In US And China: Practical And Effective Tax Strategies"</i>
	James Shen , PhD, Import Compliance Officer, FDA <i>"Requirements Of Laws And Regulations Enforced By FDA Concerning Medical And Pharmaceutical Products"</i>
	Quanyin Gao , PhD, Director, Analytical Development Irvine Pharmaceutical Services, Inc. <i>"Systematic Approach to Extractable and Leachables Studies"</i>
2:30 pm	Special Report from China I: Andrew Pan , North America Representative Office of Shenzhen, China <i>"Succeeding In Global Business Operations"</i>
2:40 pm	Coffee Break
Section IV	VC Panel: Achievable Success in Venture Funding Moderator: Paul DeRidder , MD, Crystal Cove Capital
3:00 pm	Paul DeRidder , MD, MBA, Venture Partner- Crystal Cove Capital , Partner- Ampleluck International Capital Group , Ltd, Beijing <i>"Venture Funding 2008, Is There Light at the End of Tunnel for 2009?"</i>
	Sofie Qiao , PhD, Founder, Senior VP, Managing Director of Chinese Operations, Lead Therapeutics , Inc <i>"The Long LEAD to Venture Funding"</i>
	Darin Chen , JD, MBA, Managing Director, Hillcrest Venture Partners <i>"Investment Criteria in the New Global Economy"</i>
	John Shu , Attorney, Stradling Yocca Carlson & Rauth <i>"Legal Risk Assessment for Venture Funding"</i>
4:10 pm	Special Report from China II: Chen Chen , Biobay, Suzhou, China <i>"Innovation Center in Suzhou Industrial Park with Focus on Biotech and Nanotech"</i>
4:20 pm	Closing Remarks Zhongping Chen , PhD Professor of Bioengineering at Beckman Laser Institute, SABPA Board Member

Speaker Biographies



Hengchu Cao, Ph.D.
Distinguished Engineer, Edwards Lifesciences
President, SABPA OC/LA

Dr. Hengchu Cao has 20 yrs of work experience, with 15yrs in class III implantable medical devices. He has a strong technical and scientific background, especially in computer modeling (FEA/CFD), materials development (biocompatible metals, polymers and ceramics), fatigue life analysis, reliability, device testing, design and analysis. Dr. Cao also has strong technical leadership skills in managing R&D project teams. He has extensive experience in supporting product FDA approvals through 510(k), IDE and PMA processes. Dr. Cao devotes considerable effort to promote the technical excellence in biotech and biomedical engineering profession in the southern California region. He took part in the inaugural biotech and medical device forum by SABPA OC/LA chapter and co-Chaired the second Biomedical Forum. He is elected Board of directors for SABPA and serves as the current president for the Orange County/Los Angeles Chapter. Dr. Cao has co-chaired the Annual ASME Frontiers in Biomedical Devices Conference and Exhibition in 2008. He holds a BS in chemical engineering from South China University of Technology, and a PhD in materials science from University of California at Berkeley. Dr. Cao has over 30 technical publications and holds several patents. He was named in the American Men and Women of Sciences.



Goran Matijasevic, Ph.D., MBA
Director of Research Development, UC Irvine
School of Engineering

Goran Matijasevic is Director of Research Development at [The Henry Samueli School of Engineering](#) at UC Irvine. In this capacity, he works on formation of new industry-university and academic collaborations, especially focusing on new interdisciplinary research initiatives. Prior to this, he was the Research Coordinator of the [Integrated Nanosystems Research Facility](#) at UC Irvine, where he worked closely with industry partners on making them aware of available university resources. Prior to UCI, he worked as a senior engineer at Qplus and Director of Research at Ormet Technologies. He has 4 U.S. patents, 3 book chapters, and over 40 conference and journal publications and has served on the NEMI Industry Roadmap committee. He served as NanoWorld Conference Technical Chair, the Electronic Components and Technology Conference (ECTC) Interconnect Chair and Emerging Technologies Chair, the IEEE Sensors 2006 Local Chair, the ASME Frontiers in Biomedical Devices Co-Chair, as well as on the LARTA Tech Transfer Conference Organizing Committee. He is currently on the OCTANe (Orange County Technology Action Network) Leadership Committees. He is a member of the TriTech Advisory Board, and the Board of the Southern California Biomedical Council and is on the Advisory Board of SABPA. Goran received his PhD from UC Irvine in Electrical and Computer Engineering and his MBA from Pepperdine University. He may be reached at goran@uci.edu.



Shouyan Lee, PhD, Medical Implant Mechanics, LLC


Shouyan Lee, Ph.D. brought in more than twenty years of experience and expertise in experimental fluid mechanics and customized medical device testing.

Dr. Lee graduated from University of California San Diego with a Ph.D. in Bioengineering in 1993.



Rob Michiels, Chief Operating Officer, CoreValve, Inc.

Mr. Michiels is a three decade veteran of the medical device industry. He previously served as President/COO of Interventional Technologies an interventional cardiology company, and as Chief Executive Officer of VenPro, a cardiac implant company. He is a founding partner of CONSILIUM, a medical device market research company that is active in identification and funding of start-up technologies. He holds a bachelor's degree in economics from Antwerp University in Belgium and a MBA from Indiana University.



Peter C. Chen, Ph.D.
President, Center for Innovation and Strategic
Collaboration, St. Jude Medical, Inc.

Dr. Peter Chen has more than 25 years of experience in the medical device industry. He is the Founder of Irvine Biomedical , Inc. (IBI), a St. Jude Medical Company. Dr. Chen established IBI in 1995, and had successfully led the Company to develop, launch, and market electrophysiology products around the world. He was able to grow IBI into a multi-million dollar company before being acquired by St. Jude Medical, one of the largest global medical device companies, in 2004. After the acquisition, Dr. Chen continued his position as the President of IBI and led the company to increase its business at 33% annually and to generate a sales revenue of over \$110 million in 2008. Dr. Chen is well known in the field of Electrophysiology and Cardiac Rhythm management through his innovative invention of new devices for treating cardiac arrhythmias. He is the author and co-author of more than 15 patents and 20 publications. Recently, Dr. Chen has been named as the President of a newly created division, Center for Innovation and Strategic Collaboration, of St. Jude medical. Dr. Chen obtained his Master degree in Electrical Engineering from the University of Kansas and earned his Ph.D. degree in Biomedical Engineering from Rutgers, the State University of New Jersey.

Prior to founding IBI, Dr. Chen held several key R & D positions in some of the major medical device companies including Baxter Health Care, Guidant Corp, Chiron and Johnson & Johnson.

Dr. Chen was named in the 2006-2007 Strathmore's WHO's WHO. He was also named as Honorary Chairman, Business Advisory Council of The National Republic Congressional Committee in 2003 and 2007.



Stan Rowe, Corporate Vice President, Advanced Technology and Chief Scientific Officer, Edwards Lifesciences Corporation

Stan Rowe is Corporate Vice President, Advanced Technology & Chief Scientific Officer at Edwards Lifesciences Corporation. He previously served as president and CEO of Percutaneous Valve Technology Inc., which was acquired by Edwards in January 2004. Prior to PVT, which he helped to found in 1999, Rowe was corporate vice president of Business Development and Strategic Planning for Datascope Corp. Prior to this, he was vice president of Business Development for Johnson & Johnson's Interventional Systems Division (JJIS), responsible for the company's coronary stent development efforts. At JJIS and the related Cordis Corporation, Rowe held a variety of positions with increasing levels of responsibility, including heading the company's Business Development, Advanced Technology, Worldwide Clinical Research, and Marketing groups. Rowe joined Cordis after having held several positions in product management for various medical device companies. He holds a bachelor's degree from the University of Alabama. He also sits on the board of directors of both Remon Medical Ltd. and Biomerix Corp.

Alex Qiu, MD, PhD, Allergan, LLC



Mitchell Brin, M.D., Senior Vice President, Global Drug Development & Chief Scientific Officer BOTOX®, Allergan, LLC. & Clinical Professor of Neurology, University of California, Irvine

Dr Brin was one of the pioneers in the use of botulinum toxin and began experimental pharmacology studies on this topic in 1984. He has extensive clinical development experience with 25 years of pharmacology, experimental therapeutics, small molecule and neurotoxin (including Oculinum® / BOTOX® / Myobloc® / Dysport®) research on a background of extensive patient care. Dr. Brin graduated with a Bachelor of Arts degree in Biology from the University of Pennsylvania and received his Medical Degree from Columbia College of Physicians and Surgeons. In 1994, he initiated his clinical research career at Columbia University Neurological Institute. In 2001, Dr. Brin joined Allergan to oversee the Global Drug Development program in neurotoxins and small molecules for neurologic diseases. He is currently the Chief Scientific Officer for BOTOX®. In this capacity, he provides strategic cross-functional oversight of the neurotoxin and next generation biologics franchise. He continues seeing patients at the University of California, Irvine in the department of Neurology, where he continues to publish actively and maintains his Professorship.

Hua Zhu (David) Ke, Ph.D., M.D.
Scientific Executive Director, Bone and Mineral Metabolism, Amgen Inc., Thousand Oaks, California, and Adjunct Professor, Department of Radiology, University of Utah School of Medicine, Salt Lake City, Utah

Dr. Ke's primary research interests include bone biology, osteoporosis and orthopedic related research, and the application of basic science to drug discovery research. Specifically, his research areas include selective estrogen receptor modulators (SERMs), estrogen receptor alpha and beta and their regulation on bone metabolism, androgen and selective androgen receptor modulator, prostaglandin E receptors and their skeletal effects, OPG/RANK/RANKL and their regulations on bone resorption, etc. Most recently he and his group have focused on the research related to osteoblasts regulation, specifically the sclerostin pathway and its role on bone formation. He has authored or co-authored approximately 90 scientific papers in the peer-review scientific journals; giving many scientific presentations in the national and international scientific meetings and invited seminars; and is an inventor or co-inventor of more than 30 patents. He is the co-discoverer and principal investigator of three novel drug candidates that are in different stages of clinical trials for prevention and treatment of osteoporosis and fracture repair. Dr. Ke was a Research Fellow in Pfizer Global Research and Development for more than 13 years before joining Amgen in 2005 and has served as the head of Amgen bone research group since.



Scott Lopez, MBA
 Medical Device Sales and Marketing
 Orange County and Inland Empire Southern
 California, Biotronik, Inc.

Mr. Lopez is responsible for sales and marketing of the Biotronik Cardiac Rhythm Management product line within South Orange County, Riverside and Temecula, CA. As a clinical advisor and technical specialist, Mr. Lopez also attends device implant procedures at hospital cardiac catheterization labs and operating rooms. Responsibilities include case flow, programming and troubleshooting pacemakers, implantable cardioverter-defibrillators and heart failure devices.

Pursuing his passion for International business and trade, Mr. Lopez also works to connect Southern California biomed and healthcare firms with overseas partners. International transactions include: joint venture, trade promotion, distribution and import / export activities.

Prior to joining Biotronik, Inc. Mr. Lopez was an officer in the United States Marine Corps for 10 years and served as an F/A-18 pilot and Public Affairs Officer in Southern California and the Middle East. His corporate sales career includes working for Boston Scientific, EchoStar and Starz Encore Group. He has been a successful business owner.



Sabing H. Lee, J.D.
 Knobbe, Martens, Olson & Bear, LLP

Sabing H. Lee is a partner in the Orange County office of Knobbe, Martens, Olson & Bear, LLP. Mr. Lee received his Bachelors Degree in Materials Engineering, Phi Beta Kappa and *summa cum laude*, from UCLA, and also received his Masters Degree in Materials Science and Engineering from UCLA. He received his J.D. from the University of California, Berkeley School of Law (Boalt Hall), where he was an Articles Editor and Executive Editor for the Berkeley Technology Law Journal. Mr. Lee's practice includes strategic patent procurement, patent portfolio management, general counseling on infringement and licensing, interferences, reexaminations, and other related issues. Mr. Lee

currently represents clients in a wide range of technologies, including medical devices, nanotechnology, and semiconductor fabrication. Mr. Lee joined the firm in 1997 and became a partner in 2003. He was named as one of Southern California's "Rising Stars" in intellectual property law in a survey of his peers, published in Los Angeles magazine and Super Lawyers magazine, in 2004, 2005, 2006 and 2007. In the medical device field, Mr. Lee has worked extensively with cardiovascular, orthopedic and aesthetic technologies. He has been involved in the intellectual property strategy and acquisitions of PercuSurge, Inc. (acquired by Medtronic, Inc.), Flex-Foot, Inc. (acquired by Össur hf.) and Endius, Inc. (acquired by Zimmer Holdings, Inc.).

Cliff C. Guan, Senior Manager, International
 Tax – China Desk Leader, Pacific Southwest
 Region, Deloitte Tax LLP

Cliff is the China Desk Leader based in the Los Angeles office. He is an international senior manager with 11 years of U.S. tax experience, including two years as a director for an S&P 500 company. Prior to his U.S. career, Cliff worked in China and Hong Kong for one of the largest Chinese enterprises. During his twenty year career, Cliff has developed deep and broad knowledge and expertise with respect to business and taxation in the U.S. and China. His understanding of the legal, tax, and business landscape in these countries enables him to provide practical and effective tax and business advice.

Cliff has extensive experience in real estate investment trusts and partnerships. He has participated in mergers & acquisitions with a cumulative value of US \$10 billion. His experience includes international tax and business consulting services for inbound and outbound U.S. investments. During his rotation in the Deloitte China Beijing office, he has developed expertise in China's new enterprise law. Cliff is a certified public accountant and a member of California Society of CPA and American Institute of CPAs. Cliff holds a Master of Business Taxation from University of Southern California, and Master of Economics & Bachelor of Science from Peking University, China.

C. James Shen, Ph.D.
Import Compliance Officer, FDA

Dr. Shen is an Import Compliance Officer in the Los Angeles District, FDA. His primary responsibility is to ensure that the FDA regulated products including medical and pharmaceutical products meet the FDA requirements. Dr. Shen has more than 30 years experience in FDA laws and regulations, and FDA's enforcement processes. He started his FDA career in 1978, served variety positions within FDA including Research Chemist, Food Additives Policy Specialist, Supervisory Chemist, Domestic Compliance Officer, Acting Watch Commander, Acting Import Branch Director, Acting Deputy Division Director of Field Science and Acting San Juan District Director. Dr. Shen obtained his B.S. of biology in 1970 from Tunghai University in Taiwan, and received Ph.D. for Nutritional Biochemistry in 1978 from University of Illinois, Urbana, IL. He also obtained Senior Executive Fellow Certificate from Harvard University, Cambridge, MA in 2004.



Quanyin Gao, Ph. D.
Director, Analytical Development
Irvine Pharmaceutical Services, Inc.

Dr. Quanyin Gao received his B. Sc. in Chemistry from Nanjing University, and MS in Physical Chemistry from Dalian Institute of Chemical Physics, Chinese Academy of Science. He continued his education at the University of California, Irvine, where he received a Ph.D. in Physical Chemistry. He worked as a post Doctoral at Chemistry Department at University of Pittsburgh on Solid State Chemistry and at Pacific Northwest National Laboratories on Bio Mass Spectrometry.

Later, he joined Teva Pharmaceuticals as a Sr. Scientist in R&D Department. He also worked in B. Braun Medical Inc. as a Sr. Staff Scientist on leachables and extractables before joining Watson Pharmaceuticals. At Watson Pharmaceuticals Inc. as an Associate Director in R&D analytical, he worked with a team of chemists on new product development for solid dosage form products and inhalation products with more than 20 ANDA and DMF filings. Currently, he is a Director of Analytical Development at Irvine Pharmaceutical Services, Inc. working on projects supporting pharmaceutical, medical device,

biopharm, and nutraceutical developments. He authored a book chapter of "Analytical Methods Development and Methods Validation for Solid Oral Dosage Forms" with colleagues for a book Generic Drug Product Development (Marcel Dekker, New York, 2004, Ed. L. Shargel and I. Kanfer). He also serves as an USP Expert Committee member of Pulmonary and Steroid Monograph Development. His research area includes solid state chemistry, bio mass spectrometry, separation science, and pharmaceutical analyses.



Andrew M. Pan
Chief Representative and Managing Director
North American Representative Office of Shenzhen, P.
R. China (NAROS)

Andrew M. Pan is the primary official contact of the City of Shenzhen in North America and oversees the daily operation of Los Angeles based NAROS which is a bilateral trade and investment promotion office of Shenzhen that gives support and free services for North American companies to do business in Shenzhen and other parts of China, as well as for Shenzhen companies to do business in the North America.

With his years of experience both in China and the U.S., Mr. Pan is a seasoned consultant on market entry, business development, sourcing and outsourcing, as well as government relations for overseas companies to do business in China and for China based companies to develop "Go Global" strategies.

Prior to NAROS, Mr. Pan served as the director of Foreign Investment Promotion of Shenzhen Bureau of Trade and Industry (SZBTI), the director of Economic Development of Shenzhen Free Trade Zone Administration (SZFTZ), and the senior manager of Shenzhen Foreign Investment Service Center (SZFIS).

Mr. Pan received a master of economics from Shanghai University of Economics and Finance and a bachelor of economics from University of International Relations, Beijing.



Paul A. DeRidder, M.D., MBA
Venture Partner, Crystal Cove Capital, LLC;
Executive Committee, TCA

Dr. Paul DeRidder is a venture partner at Crystal Cove Capital, LLC and an Executive Committee member for Tech Coast Angels. Dr. DeRidder is a board-certified urologist, receiving his medical training at the University of Michigan School of Medicine. He was in private clinical practice for twenty-two years, and is a past Assistant Clinical Professor of Urology in the Department of Surgery at University of California, Irvine. Dr. DeRidder is a Diplomate of The American College of Physician Executives. He has been co-founder and CEO of several specialty management organizations, and was a co-founder and board member of Urotherapies, Inc., a nationally based single specialty management group dedicated to the enhancement of Urologic specialty care. Dr. DeRidder holds several patents on various medical devices. Dr. DeRidder was a charter member of the University of California, Irvine's Healthcare Executive MBA program, and completed his MBA in November 1997. He is a Charter Member of the Executive Committee of the Deans Leadership Group at the University of California, Irvine, Paul Merage School of Business.



Sofie Qiao, Ph.D., Founder, Senior VP,
Director of Chinese Operations
Lead Therapeutics, Inc

Dr. Qiao was previously Director of Business Operations at Discovery Partners International, Inc. (DPI), a San Diego-based drug discovery CRO, with responsibilities in business development, strategic initiatives and marketing. Prior to DPI, she was Director of Business Development at Syrrx, Inc., a venture-backed structure-based drug discovery company. She started her industry career as a medicinal chemist in small molecule drug discovery at Genzyme Corporation, and transitioned to the business side by joining McKinsey & Company, where she

focused on pharmaceutical and biotech clients. She received her Ph.D. in organic chemistry at MIT, and her A.B. in chemistry from Harvard University. A native of Beijing, China, she started her undergraduate studies at Peking University, and transferred after two years to Harvard. She currently serves on the Board of Directors of Sino-American Biomedical and Pharmaceutical Professionals Association (SABPA).



Darin Chen, J.D., MBA, Managing Director,
Hillcrest Venture Partners

Darin Chen is a co-founder and Managing Director of Hillcrest Venture Partners. Prior to co-founding Hillcrest, Darin was Senior Associate at Arcturus Capital, where he evaluated and sourced investment opportunities. Darin represented the firm as board observer to High Throughput Genomics, one of the firm's portfolio companies. Darin began his career in venture capital as an Analyst at Hopewell Ventures, where he evaluated deal flow and helped raise the firm's inaugural fund. Before Hopewell, Darin co-founded Lan-CE, an industrial process improvement company, and E-volutionet.com, an Internet exchange for the procurement of services. Prior to his entrepreneurial work, Darin was an Associate at the law firm of Schaffer & Baumer, where he specialized in corporate law and represented cancer research organizations. Darin worked as a Research Scientist at Immunosciences Laboratories, a clinical immunology laboratory, before he began practicing law.

Darin also serves on the investment screening committee for the Southern California Biomedical Council Investor Conference, as a company mentor for the NIH Commercialization Assistance Program, and on venture panels for CONNECT and OCTANe.

Darin has a BA in Molecular Biology from Rice University, a JD from Loyola University of Chicago, and an MBA from the University of Chicago, graduating near the top of his class.

John Shu, Attorney, Stradling Yocca Carlson & Rauth

John Shu is an attorney with Stradling Yocca Carlson & Rauth in Newport Beach, California. Mr. Shu served as a law clerk to the Honorable Paul H. Roney, U.S. Court of Appeals for the 11th Circuit, and as a judicial extern to the Honorable Stanley Sporkin, U.S. District Court for the District of Columbia. Mr. Shu served in the White House under President George H.W. Bush and in Bush/Cheney Transition Headquarters under President-elect George W. Bush. Mr. Shu has lived and studied in Asia, and has spoken on a number of legal, bio-technology, political, international relations, and foreign policy issues. Mr. Shu is a Term Member of the Council on Foreign Relations, a Member of the Foreign Policy Association, the National Committee on U.S.-China Relations, and the Pacific Council on International Policy. Mr. Shu has a B.A. from the University of Pennsylvania, a G.C. from Peking University, and J.D. from Pepperdine University.



Zhongping Chen, Ph.D. Professor, Biomedical Engineering, UC Irvine, and Cofounder, Director, OCT Medical Imaging, Inc.

Dr. Zhongping Chen is a Professor of Biomedical Engineering and Director of OCT Imaging Laboratory at UCI. He is a Co-Founder of OCT Medical Imaging, Inc. Dr. Chen's research interests encompass the areas of biomedical photonics, microfabrication, biomaterials and biosensors. His group has developed functional optical coherence tomography, a new medical imaging modality that allows cross-sectional imaging of tissue structure, blood flow, and birefringence simultaneously with high spatial resolution. Dr. Chen has published more than 100 peer-reviewed papers and review articles and holds a number of patents in the fields of biomaterials, biosensors, and biomedical imaging. Dr. Chen received his B.S. degree in Applied Physics from Shanghai Jiao Tong University in 1982, his M.S. degree in Electrical Engineering from Cornell University in 1987, and his Ph.D. degree in Applied Physics from Cornell University in 1992. He is the fellow of American Institute of Medical and Biological Engineering.

Sponsors Description

St. Jude Medical is dedicated to developing medical technology and services that put more control in the hands of physicians, and that advance the practice of medicine and contribute to successful outcomes for every patient. We strive for continuous improvement in everything we do, every day. We are committed to consistently meeting the highest quality standards and operating in a highly disciplined environment, backed by rigorous business ethics. It is our mission to develop medical technology and services that put more control into the hands of those who treat cardiac, neurological and chronic pain patients, worldwide. We do this because we are dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. For more information, please visit <http://www.sjm.com>.

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring, with more than five decades of experience in partnering with clinicians to develop life-saving innovations. Headquartered in Irvine, Calif., Edwards treats advanced cardiovascular disease with its market-leading heart valve therapies, and critical care and vascular technologies, which are sold in approximately 100 countries. The company's global brands include Carpentier-Edwards, Cosgrove-Edwards, Edwards SAPIEN, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at <http://www.edwards.com/>.

Knobbe Martens Olson & Bear LLP, currently the third largest IP firm nationwide, is a law firm practicing exclusively in the area of intellectual property law including patents, trademarks, copyrights, trade secrets, rights of publicity, unfair competition, and related litigation and licensing. The firm maintains offices in Orange County, San Diego, San Francisco, Los Angeles, Riverside, Washington D.C., and Seattle. Services are provided to clients throughout the United States and the world. At present, the firm is composed of more than 250 lawyers and other professionals, nearly all of whom hold undergraduate or graduate degrees in either engineering or the technical sciences. This combination of law and technology makes Knobbe Martens uniquely qualified to represent a diverse array of clients in a broad spectrum of intellectual property matters. For more information, please visit <http://www.kmob.com/>.

North American Representative Office of Shenzhen, P. R. China (NAROS) is a U.S. based free business service provider representing the City of Shenzhen, the first Special Economic Zone in China, and the biggest import and export city among all mainland China cities. Sponsored by the Municipal Government of Shenzhen and the Shenzhen Bureau of Trade and Industry (SZBTI), NAROS gives free support and services for all North American companies interested in business in Shenzhen and other parts of China. NAROS also supports and services Shenzhen companies interested in North America. For more information, please visit <http://www.shenzhenoffice.org/>.

BioBay is located in the southwest of Suzhou Industrial Park's Dushu Lake Higher Education Town, in Jiangsu, China. Suzhou Industrial Park (SIP) is the largest cooperation program between China and Singapore, and is committed to building a globally competitive high-tech industrial park. BioBay is a key driver for innovation and a key focus of growth at SIP, and is a leader in the development of bio and nanotechnology throughout China. For more information, please visit <http://www.biobay.com.cn>

Medical Implant Mechanics LLC (MIM) was founded by Xiao-Yan (XY) Gong, Ph.D. in August 2006 to meet the increasing demands of mechanics in medical device and implant industry. With the mission to provide customers world class mechanics services of the highest quality in the shortest time, MIM has successfully supported start-up companies and well-established industrial giants alike. MIM has established its brand name to help our clients succeed in more than a billion dollars worth of projects. For example, one of our local clients, CoreValve Inc. was recently acquired by Medtronic for more than 700 million US dollars as a first payment. For more information, please visit <http://www.medicalimplantmech.com>.

SIMULIA is the Dassault Systèmes brand that delivers a scalable portfolio of Realistic Simulation solutions including the Abaqus product suite for Unified Finite Element Analysis, multiphysics solutions for insight into challenging engineering problems, and SIMULIA SLM for managing simulation data, processes, and intellectual property. By building on established technology, respected quality, and superior customer service, SIMULIA makes realistic simulation an integral business practice that improves product performance, reduces physical prototypes, and drives innovation. Headquartered in Providence, RI, USA, SIMULIA provides sales, services, and support through a global

network of regional offices and distributors. For more information, visit <http://www.simulia.com>.

Integrium is a full-service Clinical Research Organization (CRO) exclusively dedicated to the management of cardiovascular and metabolic disease clinical trials. We combine our focused clinical expertise with strong operational capabilities to deliver the highest level of customer care. Within our singular therapeutic focus, our vast trial experience spans across all stages of clinical development and stretches around the globe, from single region, proof-of-concept studies to multinational pivotal trials with more than 6,000 subjects

Founded and guided by thought leaders in cardiovascular and metabolic disease research, Integrium has a distinct advantage when designing and executing cardiovascular and metabolic disease clinical trials. The clinical expertise of our founders and staff, as well as to our network of high-enrolling investigators, has resulted in a proven track record of success.

For the convenience of our clients, Integrium offers each of our clinical trial services as part of a single, turnkey solution or on a stand-alone basis. Regardless of whether you use one of our services or the full spectrum, we will perform our services with the highest level of customer service. We invite you to learn more about Integrium's unique menu of services:

- Program Planning and Feasibility
- Study Design and Protocol Development
- Study Start-Up Services
- Project Management
- Site Monitoring
- Drug Safety and Medical Monitoring
- Data Management
- Biostatistics and Statistical Programming
- Medical Writing

For more information, please visit www.integrium.com

Pharmatek Laboratories, Inc. is a premier pharmaceutical chemistry development organization supporting the pharmaceutical and biotechnology industries. Pharmatek focuses on bringing client compounds from discovery to the clinic with services that include compound selection, analytical development, preformulation testing, formulation development, GMP manufacturing, ICH stability storage and testing, and high-potent & cytotoxic development and manufacturing. For more information, please visit <http://www.Pharmatek.com>.

NeuroMed Devices, Inc. is the world's foremost innovator of non-invasive therapeutic neuromodulation. With its internationally patented and clinically proven approaches to neuromodulation, the company will be introducing a variety of safe and effective devices for the treatment of a wide array of neurological indications. This site will be updated as appropriate to announce the availability of various approved products around the world.

Irvine Pharmaceutical Services, Inc. is a FDA registered premier pharmaceutical development organization providing integrated CMC support from preclinical to post-market-life-cycle management. With an emphasis on excellence in project management, a cornerstone of Irvine's customer-focused approach, coupled with steady and continuous growth or services and expertise, Irvine continues to exceed client expectations.

Irvine's extensive list of services includes:

- Biopharmaceutical Support
- Structural Chemistry Support
- Inhalation/Nasal and Transdermal Device Testing
- Pre-formulation and Formulation Support
- Method Development and Validation
- Analytical Quality Control Testing
- Stability Storage and Testing
- Microbiological Support

To learn more, visit www.irvinepharma.com or call (877) 445-6554.

Conference Organizing Committee

Name	Function	Affiliation
Hengchu Cao	President, SABPA OC/LA	Edwards Lifesciences
Paul DeRidder	Executive Vice President	Crystal Cove Capital
Peggy Fu	VP of Legal Affairs	Paul Hastings
Fred Ouyang	VP of Fundraising	Allergan, Inc
Joy Liu	VP of Membership	Aubrey Group
Teresa Wong	VP of Events	Clinical Data Consultants
Goran Matijasevic	VP of University Relations	UC, Irvine
Ying Zhao	VP of Organizational Development	Thorlabs Inc.
Zhongping Chen	Advisor	Beckman Laser Institute, UCI
G. P. Li	Advisor	Callt2, UCI
Vivian Chang	Treasurer	Merrill Lynch
Bing Leng	Registration	Genevault
Bin Tian	Publication	Edwards Lifesciences
Henry Li	Webmaster	Edwards Lifesciences
Alex Qiu	Chair, Biotechnology Committee	Allergan, Inc
Peter Chen	Chair, Medical Devices Committee	St. Jude Medical
Shouyan Lee	Chair, Pacific Alliance Committee	Medical Implant Mechanics
Scott Lopez	Chair, Entrepreneur Committee	Biotronik, Inc.
Esmaeil Heidari	Career Development	UC Irvine
Joy Yang	Event Promotion	Irvine Pharmaceutical Services
Katherine He	External Relations	Edwards Lifesciences
Jay Li	Social Program	Beijing Gingko Group, North America Inc
Jin Luo	Technical Program	Irvine Chemistry Laboratory
John Shu	VC Funding	Stradling Yocca Carlson & Rauth

Quanyin Gao	CRO Services	Irvine Pharmaceutical Services
Xiangming Fang	SABPA SD President	Pfizer
Hui Cai	SABPA Board Chair	Johnson & Johnson
Ming Guo	SABPA Board Member	Ascenta Therapeutics
Mingzhu Zhang	SABPA Chair - Fund Raising	Shanghai Medicilon

For more information about membership and sponsorship, please contact <mailto:sabpa.ocla@gmail.com>